Sigyn Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS??? EQUITY (Details Narrative)

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)													1 Months Ended	12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Nov. 03, 2021	Oct. 28, 2021	Oct. 25, 2021	Oct. 22, 2021	Oct. 20, 2021	Oct. 20, 2021	Oct. 14, 2021	Jul. 14, 2021	May 10, 2021	Apr. 14, 2021	Jan. 14, 2021	Oct. 19, 2020	Apr. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Feb. 19, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares authorized														1,000,000,000	1,000,000,000
Common stock par value														$ 0.0001	$ 0.0001
Common stock shares outstanding														37,295,803
Stock issued during period shares										47,000	47,000
Stock issued during period value										$ 82,250	$ 82,250
Repayments of Debt	$ 20,000
Shares issued	15,000
Debt conversion, amount									$ 110,000
Debt conversion, shares issued									157,143
Stock issued during period shares							47,000	47,000	1,172,000
Aggregate numbers of warrants to purchase shares									1,172,000
Proceeds from issuance of common stock									$ 1,465,000				$ 1,500,000
Stock issued during period value							$ 37,600	$ 47,000							$ 610,181
Sale of stock, description													The offering allowed for qualified investors to purchase one share of the Company’s common stock $1.25. For each share purchased, the investor received a five-year warrant to purchase one share of common stock at $1.75 per share
Shares issued price per share													$ 1.25
Stock issued during period, shares acquisitions												33,686,169
Previous Noteholder [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate numbers of warrants to purchase shares																57,147
Third Parties [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares															1,015,344
Convertible Promissory Note [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares				450,000
Proceeds from issuance of common stock				$ 197,501
Debt instrument maturity date				Oct. 20, 2022
Term of warrants				5 years
Exercise price of warrants per share				$ 1.00
Other expenses														$ 40,041	$ 0
Securities Purchase Agreement [Member] \| Convertible Promissory Note [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares						320,000
Aggregate numbers of warrants to purchase shares					320,000	320,000
Proceeds from issuance of common stock					$ 400,000
Debt conversion, description						The offering allowed for qualified investors to purchase one share of the Company’s common stock at $1.25. For each share purchased, the investor received a five-year warrant to purchase one share of common stock at $1.25 per share
Osher Capital Partners LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt conversion, amount		$ 16,714
Debt instrument carrying amount		$ 199,650
Debt conversion, shares issued		42,857
Osher Capital Partners LLC [Member] \| Marketing Consulting Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt instrument carrying amount			$ 110,000
Debt conversion, shares issued			157,143
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares														500,000
Stock issued during period value														$ 50